SK288094B6 - Protein product based on truncated neurotrophic factor, polynucleotide encoding this protein product, vector comprising such polynucleotide, prokaryotic or eukaryotic host cell transformed or transfected with such polynucleotide, process for obtaining said protein product, pharmaceutical composition comprising the protein product, process for preparing this composition and use said product - Google Patents

Protein product based on truncated neurotrophic factor, polynucleotide encoding this protein product, vector comprising such polynucleotide, prokaryotic or eukaryotic host cell transformed or transfected with such polynucleotide, process for obtaining said protein product, pharmaceutical composition comprising the protein product, process for preparing this composition and use said product Download PDF

Info

Publication number
SK288094B6
SK288094B6 SK389-98A SK38998A SK288094B6 SK 288094 B6 SK288094 B6 SK 288094B6 SK 38998 A SK38998 A SK 38998A SK 288094 B6 SK288094 B6 SK 288094B6
Authority
SK
Slovakia
Prior art keywords
gdnf
protein
arg
engineered
amino acid
Prior art date
Application number
SK389-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK38998A3 (en
Inventor
Shaw-Fen Sylvia Hu
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of SK38998A3 publication Critical patent/SK38998A3/sk
Publication of SK288094B6 publication Critical patent/SK288094B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK389-98A 1995-09-28 1996-09-16 Protein product based on truncated neurotrophic factor, polynucleotide encoding this protein product, vector comprising such polynucleotide, prokaryotic or eukaryotic host cell transformed or transfected with such polynucleotide, process for obtaining said protein product, pharmaceutical composition comprising the protein product, process for preparing this composition and use said product SK288094B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/535,681 US6184200B1 (en) 1995-09-28 1995-09-28 Truncated glial cell line-derived neurotrophic factor
PCT/US1996/014915 WO1997011964A1 (en) 1995-09-28 1996-09-16 Truncated glial cell line-derived neurotrophic factor

Publications (2)

Publication Number Publication Date
SK38998A3 SK38998A3 (en) 1999-07-12
SK288094B6 true SK288094B6 (sk) 2013-07-02

Family

ID=24135310

Family Applications (1)

Application Number Title Priority Date Filing Date
SK389-98A SK288094B6 (sk) 1995-09-28 1996-09-16 Protein product based on truncated neurotrophic factor, polynucleotide encoding this protein product, vector comprising such polynucleotide, prokaryotic or eukaryotic host cell transformed or transfected with such polynucleotide, process for obtaining said protein product, pharmaceutical composition comprising the protein product, process for preparing this composition and use said product

Country Status (25)

Country Link
US (5) US6184200B1 (de)
EP (1) EP0920448B1 (de)
JP (3) JP4153036B2 (de)
KR (1) KR100334739B1 (de)
CN (1) CN1283659C (de)
AT (1) ATE314389T1 (de)
AU (1) AU707528B2 (de)
CA (1) CA2232749C (de)
CZ (1) CZ297326B6 (de)
DE (1) DE69635675T2 (de)
DK (1) DK0920448T3 (de)
EA (1) EA001204B1 (de)
ES (1) ES2255713T3 (de)
HK (1) HK1021823A1 (de)
HU (1) HU226220B1 (de)
IL (6) IL144018A0 (de)
MX (1) MX9802278A (de)
NO (1) NO322521B1 (de)
NZ (1) NZ318697A (de)
SI (1) SI0920448T1 (de)
SK (1) SK288094B6 (de)
TW (1) TW570926B (de)
UA (1) UA66339C2 (de)
WO (1) WO1997011964A1 (de)
ZA (1) ZA968087B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6507788B1 (en) * 1999-02-25 2003-01-14 Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function
US6897061B1 (en) 2000-06-16 2005-05-24 Spinal Cord Society Transdifferentiation of glial cells
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US8946151B2 (en) * 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US7245117B1 (en) 2004-11-01 2007-07-17 Cardiomems, Inc. Communicating with implanted wireless sensor
ATE460183T1 (de) 2003-10-20 2010-03-15 Nsgene As Viraler vektor zur verwendung in der in-vivo- gentherapie von morbus parkinson
US20060239966A1 (en) * 2003-10-20 2006-10-26 Tornoee Jens In vivo gene therapy of parkinson's disease
JP4959566B2 (ja) 2004-08-19 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド トランスホーミング増殖因子βファミリータンパク質の折りたたみ
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
KR20090046923A (ko) * 2006-08-04 2009-05-11 프로롱 파마슈티컬스, 인크. 수식된 에리스로포이에틴
US20090069230A1 (en) * 2007-02-12 2009-03-12 The Research Foundation Of State University Of New York Gdnf-derived peptides
AU2008247637B2 (en) 2007-05-01 2013-12-05 Biogen Ma Inc. Compositions and methods for increasing vascularization
US8446454B2 (en) 2007-05-21 2013-05-21 Polycom, Inc. Dynamic adaption of a continuous presence videoconferencing layout based on video content
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
UA112981C2 (uk) * 2011-04-11 2016-11-25 Елі Ліллі Енд Компані Варіант людського gdnf
WO2014152511A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Methods for promoting wound healing and hair growth
RU2561050C2 (ru) * 2013-08-28 2015-08-20 Федеральное государственное бюджетное учреждение науки Институт биофизики клетки Российской академии наук (ИБК РАН) Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера
EP3538560A4 (de) 2016-11-10 2020-06-17 Keros Therapeutics, Inc. Gdnf-fusionspolypeptide und verfahren zur verwendung davon
US20230022970A1 (en) * 2019-12-19 2023-01-26 Transfert Plus, Société En Commandite Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
CA3238867A1 (en) 2021-11-29 2023-06-01 Shanghai Regenelead Therapies Co., Ltd. Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US5229500A (en) 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
CA1332433C (en) 1989-09-29 1994-10-11 Robert L. Sutherland Ski structure and binding therefor
ATE403713T1 (de) 1989-10-16 2008-08-15 Amgen Inc Stamzellfaktor
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5202428A (en) 1990-06-20 1993-04-13 The Salk Institute For Biological Studies DNA encoding neurotropic growth factor
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
DE69233407T2 (de) 1991-09-20 2005-09-08 Amgen Inc., Thousand Oaks Glial neurotrophe faktor
WO1995017203A1 (en) 1993-12-22 1995-06-29 The University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
FR2717824B1 (fr) 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product

Also Published As

Publication number Publication date
DE69635675T2 (de) 2006-07-06
ES2255713T3 (es) 2006-07-01
DE69635675D1 (de) 2006-02-02
EA199800301A1 (ru) 1998-10-29
US20040127419A1 (en) 2004-07-01
NO981430L (no) 1998-03-30
IL144488A (en) 2006-12-31
SK38998A3 (en) 1999-07-12
CN1283659C (zh) 2006-11-08
SI0920448T1 (sl) 2006-04-30
CZ297326B6 (cs) 2006-11-15
CA2232749A1 (en) 1997-04-03
TW570926B (en) 2004-01-11
JP4153036B2 (ja) 2008-09-17
EP0920448A1 (de) 1999-06-09
US6184200B1 (en) 2001-02-06
IL218336A0 (en) 2012-04-30
NO322521B1 (no) 2006-10-16
US7390781B2 (en) 2008-06-24
IL123761A0 (en) 1998-10-30
US20040254114A1 (en) 2004-12-16
NZ318697A (en) 1999-09-29
AU7074696A (en) 1997-04-17
HUP9802262A2 (hu) 1999-01-28
DK0920448T3 (da) 2006-04-10
EA001204B1 (ru) 2000-12-25
EP0920448B1 (de) 2005-12-28
ZA968087B (en) 1997-06-12
JP2010279360A (ja) 2010-12-16
HUP9802262A3 (en) 2001-01-29
JPH11512709A (ja) 1999-11-02
JP2008067699A (ja) 2008-03-27
KR19990063825A (ko) 1999-07-26
HK1021823A1 (en) 2000-07-07
CA2232749C (en) 2003-03-25
US20110251267A1 (en) 2011-10-13
IL123761A (en) 2005-12-18
CN1197461A (zh) 1998-10-28
WO1997011964A1 (en) 1997-04-03
JP5241037B2 (ja) 2013-07-17
AU707528B2 (en) 1999-07-15
KR100334739B1 (ko) 2002-09-17
HU226220B1 (hu) 2008-06-30
MX9802278A (es) 1998-08-30
CZ88298A3 (cs) 1999-02-17
ATE314389T1 (de) 2006-01-15
UA66339C2 (uk) 2004-05-17
IL144018A0 (en) 2002-04-21
JP4909843B2 (ja) 2012-04-04
NO981430D0 (no) 1998-03-30
US7611865B2 (en) 2009-11-03
IL144018A (en) 2012-04-30
IL144488A0 (en) 2002-05-23
US20040214776A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
JP4909843B2 (ja) 截形グリア細胞系由来神経栄養因子
US5512661A (en) Multitrophic and multifunctional chimeric neurotrophic factors
KR19990071540A (ko) 광수용체 손상 또는 변성 치룡용 제약학적 조성물
AU720092B2 (en) Glial cell line-derived neurotrophic factor receptor
JP2002505576A (ja) 神経栄養因子レセプター
WO1996034619A1 (en) Methods of preventing neuron degeneration and promoting neuron regeneration
KR100399377B1 (ko) Ｇｄｎｆ 단백질의 분석방법 및 검정 기구

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20150916